These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29804932)

  • 41. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
    Rodríguez-Arribas M; Pedro JM; Gómez-Sánchez R; Yakhine-Diop SM; Martínez-Chacón G; Uribe-Carretero E; De Castro DC; Casado-Naranjo I; López de Munaín A; Niso-Santano M; Fuentes JM; González-Polo RA
    Curr Med Chem; 2016; 23(21):2275-85. PubMed ID: 27237817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The efficacy of enzyme replacement therapy in pompe disease and secondary pathology in pompe muscle "excessive autophagy" which is relevant to the therapy resistance].
    Fukuda T
    No To Hattatsu; 2010 Mar; 42(2):114-6. PubMed ID: 23858594
    [No Abstract]   [Full Text] [Related]  

  • 44. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients.
    Feeney EJ; Austin S; Chien YH; Mandel H; Schoser B; Prater S; Hwu WL; Ralston E; Kishnani PS; Raben N
    Acta Neuropathol Commun; 2014 Jan; 2():2. PubMed ID: 24383498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII).
    Nascimbeni AC; Fanin M; Masiero E; Angelini C; Sandri M
    Cell Death Differ; 2012 Oct; 19(10):1698-708. PubMed ID: 22595755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycogenosome accumulation in the arrector pili muscle in Pompe disease.
    Katona I; Weis J; Hanisch F
    Orphanet J Rare Dis; 2014 Feb; 9():17. PubMed ID: 24495340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.
    Todd AG; McElroy JA; Grange RW; Fuller DD; Walter GA; Byrne BJ; Falk DJ
    Ann Neurol; 2015 Aug; 78(2):222-34. PubMed ID: 25925726
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What else is in store for autophagy? Exocytosis of autolysosomes as a mechanism of TFEB-mediated cellular clearance in Pompe disease.
    Feeney EJ; Spampanato C; Puertollano R; Ballabio A; Parenti G; Raben N
    Autophagy; 2013 Jul; 9(7):1117-8. PubMed ID: 23669057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
    Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS
    Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.
    Han SO; Haynes AC; Li S; Abraham DM; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2020 Feb; 129(2):73-79. PubMed ID: 31645300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid alpha-glucosidase.
    van der Ploeg AT; Kroos M; van Dongen JM; Visser WJ; Bolhuis PA; Loonen MC; Reuser AJ
    J Neurol Sci; 1987 Jul; 79(3):327-36. PubMed ID: 3302116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
    Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
    Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II).
    Lagalice L; Pichon J; Gougeon E; Soussi S; Deniaud J; Ledevin M; Maurier V; Leroux I; Durand S; Ciron C; Franzoso F; Dubreil L; Larcher T; Rouger K; Colle MA
    Acta Neuropathol Commun; 2018 Oct; 6(1):116. PubMed ID: 30382921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stbd1 is highly elevated in skeletal muscle of Pompe disease mice but suppression of its expression does not affect lysosomal glycogen accumulation.
    Yi H; Fredrickson KB; Das S; Kishnani PS; Sun B
    Mol Genet Metab; 2013 Jul; 109(3):312-4. PubMed ID: 23726947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pompe disease: from new views on pathophysiology to innovative therapeutic strategies.
    Parenti G; Andria G
    Curr Pharm Biotechnol; 2011 Jun; 12(6):902-15. PubMed ID: 21235442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycogen storage in a zebrafish Pompe disease model is reduced by 3-BrPA treatment.
    Bragato C; Carra S; Blasevich F; Salerno F; Brix A; Bassi A; Beltrame M; Cotelli F; Maggi L; Mantegazza R; Mora M
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165662. PubMed ID: 31917327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
    Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
    Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.